Wall Street Analysts See Upside Potential for 5 Stocks with Rising Price Targets

03. Natera, Inc. (NASDAQ:NTRA)

Upside Potential: 36%

On December 29, BTIG Research revised its price target for Natera, Inc. (NASDAQ:NTRA), a notable player in the genetic testing and diagnostics industry, from $75.00 to $85.00 while maintaining a Buy rating on the shares. This adjustment suggests a substantial upside potential of 36%. BTIG Research’s decision to increase the price target reflects their optimistic outlook for Natera’s future performance. The revised target underscores BTIG Research’s confidence in Natera, Inc. (NASDAQ:NTRA) position within the genetic testing and diagnostics sector, emphasizing potential growth opportunities and market trends. Investors should take note of the significant upside potential of 36% as indicated by the adjusted price target. BTIG Research’s Buy rating signals their belief that Natera is well-positioned to capitalize on advancements in genetic testing technologies and gain a competitive edge in the industry. As the genetic testing and diagnostics field continues to evolve, Natera, Inc. (NASDAQ:NTRA) may present a compelling investment prospect, according to BTIG Research’s outlook, making this research note a valuable resource for investors considering positions in the healthcare and diagnostics sector.

Alger Spectra Fund made the following comment about Natera, Inc. (NASDAQ:NTRA) in its Q2 2023 investor letter:

“Natera, Inc. (NASDAQ:NTRA) is a specialty lab providing genetic testing services in the reproductive health, oncology and transplant markets. Reproductive health tests are run to screen for common genetic disorders such as trisomy 13, 18, and 21 in pregnant women – these tests are also known as non-invasive prenatal testing (NIPT). The company’s oncology franchise is led by Signatera, a test used to detect minimal residual disease (MRD) – the applications of this test are primarily to monitor therapy response and detect cancer recurrence. Lastly, Natera’s transplant franchise is led by Prospera, a test used to monitor transplant organ rejection. Natera’s tests are all based on the company’s proprietary liquid biopsy platform to detect cell-free DNA. Shares detracted from performance this quarter after the company reported lower than expected fiscal first quarter gross margins. Moreover, we believe investors sold shares this quarter following a strong first quarter rally after the Centers for Medicare & Medicaid Services (CMS) announced they would cover Natera’s Signatera Breast tests. Despite this quarter’s decline in share price, the company reported solid quarterly revenues that beat analyst estimates, driven by strong volumes in women’s health and management raised its fiscal 2023 revenue guidance above consensus.”